pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past. Role models.

Antibody 92

Antibody Life Science Development Regulation 92

XTalks

OCTOBER 22, 2020

However, during the last months, due to COVID-19, we have observed how pharmaceutical companies have progressed very quickly through all the clinical development phases and different companies have already reached the clinical Phase III.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

pharmaphorum

DECEMBER 2, 2020

It almost hadn’t made it through clinical development, facing problems with ineffective chiral isomers and limited efficacy in animal testing, but showed such impact in human trials that it blew the competition away. Despite some setbacks, Pfizer remains one of the biggest pharma companies in the world today.

Sales 128

Sales Production Drugs Marketing 128

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

APRIL 19, 2021

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham.

Vaccination 98

Vaccination Vaccine Life Science Antibody 98

Drug Discovery World

OCTOBER 4, 2022

Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. . This year has seen some major deals announced by big pharma companies.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.

Marketing 97

Marketing Gene Silencing Gene Drugs 97

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants.

Antibody 98

Antibody Life Science Scientist Vaccination 98

XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken.

Development 105

Development Bacteria Drugs Vaccination 105

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability.

DNA 130

DNA Manufacturing Gene Therapy Gene 130